イスラエルでの子宮癌化学療法—3つのパーソナライズクリニックマッチングを取得

Israeli oncologists use chemotherapy for advanced-stage uterine cancer, recurrent disease, or aggressive subtypes like serous carcinoma. It serves as an adjuvant treatment after surgery to eliminate microscopic cells or as neoadjuvant therapy to shrink large tumors before a hysterectomy is performed.

• Treatment stages: Primarily used for stages 3 and 4 involving lymph node spread.
• Aggressive subtypes: Recommended for carcinosarcoma and clear cell cancers regardless of stage.
• Common regimens: Standard protocols typically include 6 cycles of Carboplatin and Paclitaxel.
• Advanced integration: Used alongside immunotherapy like Keytruda for metastatic or recurrent cases.

Bookimed Expert Insight: Sourasky Medical Center treats 40,000 cancer patients annually with a 90% success rate. Their specialists often combine chemotherapy with genetic testing like Foundation One CDx. This allows doctors to match specific chemo drugs to your tumor’s unique DNA profile.

Patient Consensus: Patients are often advised to request biomarker testing for PD-L1 expression before starting. This helps confirm if adding immunotherapy will improve their overall treatment response.

Oncologists in Israel primarily use a combination of carboplatin and paclitaxel (CarboTaxol) as the gold-standard first-line chemotherapy for uterine cancer. Advanced cases also utilize immunotherapy with pembrolizumab (Keytruda) or dostarlimab, often integrated with standard systemic protocols to improve survival outcomes in recurrent stages.

• First-line chemotherapy: Carboplatin and paclitaxel are standard for stage 3 or 4 endometrial cancers.
• Advanced immunotherapy: Pembrolizumab or dostarlimab target tumors with specific mismatch repair deficient (dMMR) markers.
• Targeted therapy: Doctors prescribe lenvatinib or bevacizumab to block tumor growth and blood vessel formation.
• Specialized regimens: Liposomal doxorubicin or ifosfamide effectively treat high-risk uterine sarcomas or recurrent disease.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center (Ichilov) stand out by using Foundation One CDx genetic testing. This allows specialists like Dr. Irina Stepfansky to bypass trial-and-error by matching chemotherapy drugs to your tumor's specific molecular profile. This precise approach is a key reason why the facility serves 40,000 cancer patients annually.

Patient Consensus: Many patients find that preparing for steroid-related sleep disruption or mild neuropathy helps manage the `CarboTaxol` cycle. They emphasize confirming that treatment follows NCCN guidelines, which remain the baseline for Israeli oncology care.

Chemotherapy for uterine cancer targets fast-growing cells, commonly causing fatigue, hair loss, and nausea. Standard Israeli protocols like paclitaxel and carboplatin frequently lead to bone marrow suppression and peripheral neuropathy. While most symptoms are temporary, nerve damage can persist after completing the 6-cycle regimen.

• Systemic effects: Severe fatigue cumulative across cycles typically peaks 1 week post-infusion.
• Neurological symptoms: Peripheral neuropathy causes tingling or numbness in fingers and toes.
• Hematologic changes: Bone marrow suppression reduces white blood cells, increasing infection risks.
• Physical changes: Hair loss generally begins 2 weeks after the first chemotherapy session.

Bookimed Expert Insight: Israeli oncology centers like Sourasky often pivot treatments based on real-time patient reactions. If a patient experiences an allergic response to paclitaxel, specialists like Dr. Irina Stepfansky may switch to Abraxane. This agility allows treatment to continue without compromising the 90% success rates seen at top-tier facilities.

Patient Consensus: Many patients find that bone and joint pain peaks 3 to 5 days after infusions. Using proactive pain management and preparing for a low-energy week helps manage the emotional and physical impact of treatment.

Modern uterine cancer treatments in Israel prioritize minimally invasive robotic surgery and personalized molecular therapies. Leading JCI-accredited centers like Sourasky Medical Center and Assuta Medical Center utilize Da Vinci Xi systems, targeted biological drugs, and advanced immunotherapy protocols following NCCN guidelines to ensure high success rates.

• Robotic-assisted surgery: Precision hysterectomies with Da Vinci Xi minimize pain and speed recovery.
• Targeted immunotherapy: Pembrolizumab (Keytruda) or dostarlimab treat specific genetic profiles and advanced cases.
• Fertility-sparing care: Hormone therapy including intrauterine devices allows younger patients to preserve future pregnancy.
• Advanced diagnostics: Foundation One CDx genetic testing identifies precise biomarkers for targeted therapy selection.

Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) serve over 40,000 cancer patients annually, creating a massive data pool for clinical trials. This high volume allows doctors like Irina Stepfansky to offer Phase I-III trials, providing access to emerging T-cell therapies long before they become global standards of care.

Patient Consensus: Many patients recommend requesting PD-L1 and POLEmut biomarker testing early to confirm if immunotherapy is a viable alternative to standard chemotherapy. Support networks like the Israel Cancer Association provide essential logistical guidance for families navigating long-term treatment stays.

Israeli cancer clinics manage side effects through personalized multidisciplinary protocols combining advanced genetic testing and supportive care. Hospitals like Sourasky Medical Center utilize Foundation One CDx to select targeted therapies, which reduce systemic toxicity compared to traditional chemotherapy while maintaining high treatment efficacy.

• Targeted therapy: Doctors use medications like Keytruda to attack specific cancer mutations while sparing healthy cells.
• Advanced radiation: Precision systems like the Novalis TrueBeam STx minimize damage to surrounding healthy tissues.
• Supportive pharmacology: Clinics provide advanced medications to prevent nausea, hair loss, and low blood counts.
• Fertility preservation: Specialized centers offer reliable options for patients undergoing treatments that may impact reproductive health.

Bookimed Expert Insight: Genetic profiling at clinics like Sourasky Medical Center, which treats 40,000 cancer patients annually, allows for ultra-precise dosing. Experienced specialists like Dr. Irina Stepfansky use phase I–III clinical trial data to proactively adjust protocols. This high-volume expertise often leads to fewer treatment interruptions and better long-term quality of life.

Patient Consensus: Patients emphasize requesting anti-nausea medications before infusions and monitoring blood work daily for early detection. Many recommend using urea cream for skin toxicity and staying creatively hydrated to maintain essential fluid levels.

Chemotherapy for uterine cancer in Israel is primarily administered intravenously through systemic protocols like paclitaxel and carboplatin. Most patients undergo 6 treatment cycles spaced 21 days apart. Specialists at JCI-accredited centers often integrate immunotherapy or targeted therapy for advanced cases to improve outcomes.

• Administration method: Standard delivery involves intravenous infusions via a peripheral catheter or port.
• Treatment cycle: Patients receive 1 dose every 21 days for 6 total sessions.
• Session duration: Expect 10–11 hours per visit including pre-medications and full infusion.
• Sandwich protocol: Surgeons may use 3 cycles before surgery and 3 cycles after.

Bookimed Expert Insight: Israeli oncology centers like Sourasky often perform genetic testing, such as Foundation One CDx, before starting chemotherapy. This allows doctors like Dr. Irina Stepfansky to integrate targeted therapies or immunotherapy directly into the standard systemic protocol if specific markers are found.

Patient Consensus: Expect long days at the clinic because premeds are essential to manage side effects. Patients highly value these pre-infusion treatments for significantly improving comfort during the long recovery periods between cycles.

Surgery is the primary treatment for uterine cancer in Israel, serving as both a diagnostic and therapeutic tool. Specialized gynecologic oncologists at JCI-accredited centers like Sourasky and Assuta perform hysterectomies and lymph node assessments to remove tumors and determine exact cancer staging for future care.

• Surgical methods: Hysterectomies, including total or radical approaches, remain the definitive treatment for patients.
• Nodes assessment: Sentinel lymph node biopsy reduces swelling risk by identifying only the first draining nodes.
• Minimally invasive: Surgeons utilize laparoscopic or robotic-assisted techniques to speed up patient recovery times.
• Adjuvant therapy: Chemotherapy or radiation often follows surgery based on high-risk pathology results.

Bookimed Expert Insight: While many countries focus solely on surgical removal, Israeli oncology centers like Sourasky integrate advanced genetic testing like Foundation One CDx into the surgical workflow. This allows specialists to tailor post-operative chemotherapy specifically to the tumor's DNA, often helping to avoid unnecessary treatments for low-risk patients.

Patient Consensus: Patients emphasize that specialized gynecologic oncologists deliver better results than general surgeons. They often note that chemotherapy feels like a safety net used only after surgical pathology confirms high-risk factors.